Myocardial Tissue Characterization: Histological and Pathophysiological Correlation

Current Cardiovascular Imaging Reports

Volumn 7, Issue 3, 2014, Pages 1-9

  Treibel, T A ^a   White, S K ^a   Moon, J C ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Edema; Late enhancement; LGE; Myocardial fibrosis; T1; T2

Indexed keywords

GADOLINIUM;

CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; EDEMA; EXTRACELLULAR SPACE; FIBROSIS; HEART; HEART INFARCTION; HISTOLOGY; HUMAN; IMAGE ENHANCEMENT; LATE GADOLINIUM ENHANCEMENT; MYOCARDIAL EDEMA; MYOCARDIAL SCAR; MYOCARDIAL TISSUE CHARACTERIZATION; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; RELAXATION TIME; REVIEW; SCAR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; T1 RELAXATION TIME; T2 RELAXATION TIME; TISSUE CHARACTERIZATION;

EID: 84894306734     PISSN: 19419066     EISSN: 19419074     Source Type: Journal    
DOI: 10.1007/s12410-013-9254-9     Document Type: Review

References (71)

1. Anderson KR, Sutton MG, Lie JT. Histopathological types of cardiac fibrosis in myocardial disease. J Pathol. 1979;128(2): 79-85. doi: 10. 1002/path. 1711280205.
2. Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens. 1998;16(7): 1031-41.
3. Weber KT, Brilla CG. Myocardial fibrosis and the renin-angiotensin-aldosterone system. J Cardiovasc Pharmacol. 1992;20 Suppl 1: S48-54.
4. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation. 1994;89(1): 151-63.
5. Higgins CB, Herfkens R, Lipton MJ, Sievers R, Sheldon P, Kaufman L, et al. Nuclear magnetic resonance imaging of acute myocardial infarction in dogs: alterations in magnetic relaxation times. Am J Cardiol. 1983;52(1): 184-8.
6. Garcia-Dorado D, Oliveras J, Gili J, Sanz E, Perez-Villa F, Barrabes J, et al. Analysis of myocardial oedema by magnetic resonance imaging early after coronary artery occlusion with or without reperfusion. Cardiovasc Res. 1993;27(8): 1462-9.
7. Aletras AH, Tilak GS, Natanzon A, Hsu LY, Gonzalez FM, Hoyt Jr RF, et al. Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations. Circulation. 2006;113(15): 1865-70. doi: 10. 1161/CIRCULATIONAHA. 105. 576025.
8. Tilak GS, Hsu LY, Hoyt Jr RF, Arai AE, Aletras AH. In vivo T2-weighted magnetic resonance imaging can accurately determine the ischemic area at risk for 2-day-old nonreperfused myocardial infarction. Invest Radiol. 2008;43(1): 7-15. doi: 10. 1097/RLI. 0b013e3181558822.
9. Ugander M, Bagi PS, Oki AJ, Chen B, Hsu LY, Aletras AH, et al. Myocardial edema as detected by pre-contrast T1 and T2 CMR delineates area at risk associated with acute myocardial infarction. JACC Cardiovasc Imaging. 2012;5(6): 596-603. doi: 10. 1016/j. jcmg. 2012. 01. 016.
10. Abdel-Aty H, Zagrosek A, Schulz-Menger J, Taylor AJ, Messroghli D, Kumar A, et al. Delayed enhancement and T2-weighted cardiovascular magnetic resonance imaging differentiate acute from chronic myocardial infarction. Circulation. 2004;109(20): 2411-6. doi: 10. 1161/01. CIR. 0000127428. 10985. C6.
11. Berry C, Kellman P, Mancini C, Chen MY, Bandettini WP, Lowrey T, et al. Magnetic resonance imaging delineates the ischemic area at risk and myocardial salvage in patients with acute myocardial infarction. Circ Cardiovasc Imaging. 2010;3(5): 527-35. doi: 10. 1161/CIRCIMAGING. 109. 900761.
12. Friedrich MG, Abdel-Aty H, Taylor A, Schulz-Menger J, Messroghli D, Dietz R. The salvaged area at risk in reperfused acute myocardial infarction as visualized by cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51(16): 1581-7. doi: 10. 1016/j. jacc. 2008. 01. 019.
13. Carlsson M, Ubachs JF, Hedstrom E, Heiberg E, Jovinge S, Arheden H. Myocardium at risk after acute infarction in humans on cardiac magnetic resonance: quantitative assessment during follow-up and validation with single-photon emission computed tomography. JACC Cardiovasc Imaging. 2009;2(5): 569-76. doi: 10. 1016/j. jcmg. 2008. 11. 018.
14. Dall'Armellina E, Karia N, Lindsay AC, Karamitsos TD, Ferreira V, Robson MD, et al. Dynamic changes of edema and late gadolinium enhancement after acute myocardial infarction and their relationship to functional recovery and salvage index. Circ Cardiovasc Imaging. 2011;4(3): 228-36. doi: 10. 1161/CIRCIMAGING. 111. 963421.
15. Nair V, Butany J. Heart transplant biopsies: interpretation and significance. J Clin Pathol. 2010;63(1): 12-20. doi: 10. 1136/jcp. 2009. 072462.
16. Kim RJ, Chen EL, Lima JA, Judd RM. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation. 1996;94(12): 3318-26.
17. Flacke SJ, Fischer SE, Lorenz CH. Measurement of the gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic infarction. Radiology. 2001;218(3): 703-10.
18. Kim RJ, Shah DJ, Judd RM. How we perform delayed enhancement imaging. J Cardiovasc Magn Reson. 2003;5(3): 505-14.
19. Schelbert EB, Hsu LY, Anderson SA, Mohanty BD, Karim SM, Kellman P, et al. Late gadolinium-enhancement cardiac magnetic resonance identifies postinfarction myocardial fibrosis and the border zone at the near cellular level in ex vivo rat heart. Circ Cardiovasc Imaging. 2010;3(6): 743-52. doi: 10. 1161/CIRCIMAGING. 108. 835793. The authors have taken histological validation of LGE close to a cellular level, performing extremely high-resolution ex-vivo LGE imaging on rats at 7 Tesla and compared with histological sections showing a remarkable correlation.
20. Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging. 2011;4(2): 150-6. doi: 10. 1016/j. jcmg. 2010. 11. 015.
21. Goldman MR, Brady TJ, Pykett IL, Burt CT, Buonanno FS, Kistler JP, et al. Quantification of experimental myocardial infarction using nuclear magnetic resonance imaging and paramagnetic ion contrast enhancement in excised canine hearts. Circulation. 1982;66(5): 1012-6.
22. Wesbey GE, Higgins CB, McNamara MT, Engelstad BL, Lipton MJ, Sievers R, et al. Effect of gadolinium-DTPA on the magnetic relaxation times of normal and infarcted myocardium. Radiology. 1984;153(1): 165-9.
23. Wesbey G, Higgins CB, Lanzer P, Botvinick E, Lipton MJ. Imaging and characterization of acute myocardial infarction in vivo by gated nuclear magnetic resonance. Circulation. 1984;69(1): 125-30.
24. Simonetti OP, Kim RJ, Fieno DS, Hillenbrand HB, Wu E, Bundy JM, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001;218(1): 215-23.
25. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100(19): 1992-2002.
26. Rehwald WG, Fieno DS, Chen EL, Kim RJ, Judd RM. Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury. Circulation. 2002;105(2): 224-9.
27. Fieno DS, Kim RJ, Chen EL, Lomasney JW, Klocke FJ, Judd RM. Contrast-enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing. J Am Coll Cardiol. 2000;36(6): 1985-91.
28. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343(20): 1445-53. doi: 10. 1056/NEJM200011163432003.
29. Selvanayagam JB, Kardos A, Francis JM, Wiesmann F, Petersen SE, Taggart DP, et al. Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation. 2004;110(12): 1535-41. doi: 10. 1161/01. CIR. 0000142045. 22628. 74.
30. Choi KM, Kim RJ, Gubernikoff G, Vargas JD, Parker M, Judd RM. Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function. Circulation. 2001;104(10): 1101-7.
31. Yan AT, Shayne AJ, Brown KA, Gupta SN, Chan CW, Luu TM, et al. Characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation. 2006;114(1): 32-9. doi: 10. 1161/CIRCULATIONAHA. 106. 613414.
32. Kwong RY, Chan AK, Brown KA, Chan CW, Reynolds HG, Tsang S, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation. 2006;113(23): 2733-43. doi: 10. 1161/CIRCULATIONAHA. 105. 570648.
33. Wu E, Ortiz JT, Tejedor P, Lee DC, Bucciarelli-Ducci C, Kansal P, et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart. 2008;94(6): 730-6. doi: 10. 1136/hrt. 2007. 122622.
34. Klein C, Nekolla SG, Balbach T, Schnackenburg B, Nagel E, Fleck E, et al. The influence of myocardial blood flow and volume of distribution on late Gd-DTPA kinetics in ischemic heart failure. J Magn Reson Imaging. 2004;20(4): 588-93. doi: 10. 1002/jmri. 20164.
35. Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenfus M, Parker M, et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet. 2003;361(9355): 374-9. doi: 10. 1016/s0140-6736(03)12389-6.
36. Mahrholdt H, Wagner A, Holly TA, Elliott MD, Bonow RO, Kim RJ, et al. Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. Circulation. 2002;106(18): 2322-7.
37. Kim RJ, Albert TS, Wible JH, Elliott MD, Allen JC, Lee JC, et al. Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation. 2008;117(5): 629-37. doi: 10. 1161/CIRCULATIONAHA. 107. 723262.
38. Choudhury L, Mahrholdt H, Wagner A, Choi KM, Elliott MD, Klocke FJ, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;40(12): 2156-64.
39. Wagner A, Schulz-Menger J, Dietz R, Friedrich MG. Long-term follow-up of patients paragraph sign with acute myocarditis by magnetic paragraph sign resonance imaging. Magma. 2003;16(1): 17-20. doi: 10. 1007/s10334-003-0007-7.
40. Dweck MR, Joshi S, Murigu T, Alpendurada F, Jabbour A, Melina G, et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J Am Coll Cardiol. 2011;58(12): 1271-9. doi: 10. 1016/j. jacc. 2011. 03. 064.
41. Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson. 2008;10: 54. doi: 10. 1186/1532-429X-10-54.
42. Zemrak F, Petersen SE. Late gadolinium enhancement CMR predicts adverse cardiovascular outcomes and mortality in patients with coronary artery disease: systematic review and meta-analysis. Prog Cardiovasc Dis. 2011;54(3): 215-29. doi: 10. 1016/j. pcad. 2011. 07. 003.
43. Ismail TF, Prasad SK, Pennell DJ. Prognostic importance of late gadolinium enhancement cardiovascular magnetic resonance in cardiomyopathy. Heart. 2012;98(6): 438-42. doi: 10. 1136/heartjnl-2011-300814.
44. Becker AE, Heijmans CD, Essed CE. Chronic non-ischaemic congestive heart disease and endomyocardial biopsies. Worth the extra? Eur Heart J. 1991;12(2): 218-23.
45. Kehr E, Sono M, Chugh SS, Jerosch-Herold M. Gadolinium-enhanced magnetic resonance imaging for detection and quantification of fibrosis in human myocardium in vitro. Int J Cardiovasc Imaging. 2008;24(1): 61-8. doi: 10. 1007/s10554-007-9223-y.
46. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122(2): 138-44. doi: 10. 1161/CIRCULATIONAHA. 109. 930636. The authors developed an extracellular volume technique and validated it against histology in patients with severe aortic stenosis and hypertrophic cardiomyopathy.
47. White SK, Sado DM, Fontana M, Banypersad SM, Maestrini V, Flett AS, et al. T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging. 2013. doi: 10. 1016/j. jcmg. 2013. 01. 011.
48. Miller CA, Naish JH, Bishop P, Coutts G, Clark D, Zhao S, et al. Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume. Circ Cardiovasc Imaging. 2013;6(3): 373-83. doi: 10. 1161/CIRCIMAGING. 112. 000192.
49. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008;52(19): 1574-80. doi: 10. 1016/j. jacc. 2008. 06. 049.
50. Coelho-Filho OR, Shah RV, Mitchell R, Neilan TG, Moreno Jr H, Simonson B, et al. Quantification of cardiomyocyte hypertrophy by cardiac magnetic resonance: implications for early cardiac remodeling. Circulation. 2013;128(11): 1225-33. doi: 10. 1161/CIRCULATIONAHA. 112. 000438.
51. Ugander M, Oki AJ, Hsu LY, Kellman P, Greiser A, Aletras AH, et al. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J. 2012;33(10): 1268-78. doi: 10. 1093/eurheartj/ehr481. The authors show that ECV imaging can quantitatively characterize MI, atypical diffuse fibrosis, and subtle myocardial abnormalities not clinically apparent on LGE images.
52. Wong TC, Piehler K, Meier CG, Testa SM, Klock AM, Aneizi AA, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation. 2012;126(10): 1206-16. doi: 10. 1161/CIRCULATIONAHA. 111. 089409. In this large cohort study, the authors show in unselected patients that ECV predicts outcomes at least as strongly as left ventricular ejection fraction.
53. Wong TC, Piehler KM, Kang IA, Kadakkal A, Kellman P, Schwartzman DS, et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J. 2013. doi: 10. 1093/eurheartj/eht193.
54. Piechnik SK, Ferreira VM, Dall'Armellina E, Cochlin LE, Greiser A, Neubauer S, et al. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1. 5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson. 2010;12: 69. doi: 10. 1186/1532-429X-12-69. A seminal papers for the three main T1 mapping sequences.
55. Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med. 2004;52(1): 141-6. doi: 10. 1002/mrm. 20110. A seminal paper for the three main T1 mapping sequences.
56. Chow K, Flewitt JA, Green JD, Pagano JJ, Friedrich MG, Thompson RB. Saturation recovery single-shot acquisition (SASHA) for myocardial T mapping. Magn Reson Med. 2013. doi: 10. 1002/mrm. 24878. A seminal paper for the three main T1 mapping sequences.
57. Kellman P, Wilson JR, Xue H, Ugander M, Arai AE. Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method. J Cardiovasc Magn Reson. 2012;14: 63. doi: 10. 1186/1532-429X-14-63. In this work, the authors developed and evaluated a fully automated, motion-corrected and co-registered method for producing ECV maps feasible for clinical work flow.
58. Sado DM, Flett AS, Banypersad SM, White SK, Maestrini V, Quarta G, et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart. 2012;98(19): 1436-41. doi: 10. 1136/heartjnl-2012-302346.
59. Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, et al. Noncontrast t1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013;6(4): 488-97. doi: 10. 1016/j. jcmg. 2012. 11. 013.
60. Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, et al. The identification and assessment of anderson fabry disease by cardiovascular magnetic resonance non-contrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013. doi: 10. 1161/CIRCIMAGING. 112. 000070.
61. Bull S, White SK, Piechnik SK, Flett AS, Ferreira VM, Loudon M, et al. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart. 2013;99(13): 932-7. doi: 10. 1136/heartjnl-2012-303052.
62. Puntmann VO, Voigt T, Chen Z, Mayr M, Karim R, Rhode K, et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging. 2013;6(4): 475-84. doi: 10. 1016/j. jcmg. 2012. 08. 019.
63. Ferreira VM, Piechnik SK, Dall'armellina E, Karamitsos TD, Francis JM, Ntusi N, et al. T mapping for the diagnosis of acute myocarditis using CMR: comparison to T-weighted and late gadolinium enhanced imaging. JACC Cardiovasc Imaging. 2013. doi: 10. 1016/j. jcmg. 2013. 03. 008.
64. Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15(1): 92. doi: 10. 1186/1532-429X-15-92. This document provides recommendations for clinical and research T1 and ECV measurement, addressing site preparation, scan type, scan planning and acquisition, quality control, visualisation and analysis, technical development, as well as discussing controversies in the field.
65. Robson MD, Piechnik SK, Tunnicliffe EM, Neubauer S. T measurements in the human myocardium: the effects of magnetization transfer on the SASHA and MOLLI sequences. Magn Reson Med. 2013. doi: 10. 1002/mrm. 24867.
66. Coelho-Filho OR, Mongeon FP, Mitchell R, Moreno Jr H, Nadruz Jr W, Kwong R, et al. Role of transcytolemmal water-exchange in magnetic resonance measurements of diffuse myocardial fibrosis in hypertensive heart disease. Circ Cardiovasc Imaging. 2013;6(1): 134-41. doi: 10. 1161/CIRCIMAGING. 112. 979815.
67. de Jong S, Zwanenburg JJ, Visser F, der Nagel R, van Rijen HV, Vos MA, et al. Direct detection of myocardial fibrosis by MRI. J Mol Cell Cardiol. 2011;51(6): 974-9. doi: 10. 1016/j. yjmcc. 2011. 08. 024.
68. Ugander MC, Chen MY, Chen B, Bagi PS, Hsu LY, Kellman P, Arai AE. Contrast Enhanced CT and MRI Measures of Extracellular Volume Fraction Confirm Presence of Peri-Infarct Edema in Acute Myocardial Infarction (Abstract). American Heart Association 2011.
69. Bandula S, White SK, Flett AS, Lawrence D, Pugliese F, Ashworth MT, et al. Measurement of myocardial extracellular volume fraction by using equilibrium contrast-enhanced CT: validation against histologic findings. Radiology. 2013. doi: 10. 1148/radiol. 13130130.
70. Nacif MS, Kawel N, Lee JJ, Chen X, Yao J, Zavodni A, et al. Interstitial myocardial fibrosis assessed as extracellular volume fraction with low-radiation-dose cardiac CT. Radiology. 2012;264(3): 876-83. doi: 10. 1148/radiol. 12112458.
71. Butler J, Fonarow GC, Gheorghiade M. Strategies and opportunities for drug development in heart failure. Jama. 2013;309(15): 1593-4. doi: 10. 1001/jama. 2013. 1063.